Among 30 male Veterans with traumatic brain injury from repeated blast/combat exposures, those who reported more intense mystical experiences during magnesium-ibogaine therapy showed larger reductions in PTSD severity both immediately and one month after treatment. Greater mystical experience intensity was also linked to larger reductions in peak alpha frequency one month later. The findings suggest that mystical experiences may contribute to improvements in PTSD following magnesium-ibogaine and may relate to persisting decreases in peak alpha frequency.
Ibogaine treatment in 30 male Special Operations Forces veterans with traumatic brain injury led to gradual increases in resting-state regional cerebral blood flow in cortical, limbic, and striatal brain regions, along with widespread changes in functional connectivity across multiple neural networks. The magnitude of blood flow changes in the left insula and left anterior cingulate cortex correlated with improvements in TBI-related disability symptoms. These findings suggest ibogaine may reorganize functional connections in the brain, with persisting metabolic changes in paralimbic regions potentially underlying its therapeutic effects, though larger controlled studies are needed to validate these initial results.
A single dose of magnesium-ibogaine produced large and lasting reductions in disability, posttraumatic stress disorder, depression, and anxiety symptoms over 12 months in male U.S. Special Operations Veterans with a history of traumatic brain injury. Of 30 treated participants, 25 completed the full year of follow-up. Effect sizes at 12 months were very large (Cohen's d ≥ 2.18). The estimated probability of sustained remission at one year was 84% for PTSD, 66% for depression, and 61% for anxiety. These results suggest ibogaine may offer durable clinical benefits for TBI-related psychiatric and functional problems, though randomized controlled trials are needed to confirm the findings.